RecruitingNot ApplicableNCT06270433

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder: a Multicentre, Open-label, Parallel-group, Randomised Controlled Trial


Sponsor

Jiangsu Province Nanjing Brain Hospital

Enrollment

80 participants

Start Date

Feb 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of anhedonia in patients with major depression disorder compared to desvenlafaxine succinate sustained-release tablets, to provide evidence-based basis for clinical rational drug use.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two antidepressant medications — toludesvenlafaxine and desvenlafaxine — specifically in people with major depression who also experience a loss of pleasure or enjoyment (called anhedonia). Researchers want to know which drug works better for this symptom. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with major depressive disorder - You have a high score on depression rating scales, including the anhedonia scale - You are willing to participate and sign informed consent **You may NOT be eligible if...** - You are allergic to either study medication - You have serious thoughts of self-harm or suicide - You have bipolar disorder, schizophrenia, or other serious psychiatric conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGToludesvenlafaxine hydrochloride sustained-release tablets

80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks

DRUGDesvenlafaxine succinate sustained-release tablets

50 mg orally once daily dosing for 8 weeks


Locations(1)

Nanjing Brian Hospital

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06270433


Related Trials